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Abstract 15 
Canine oral fibrosarcoma (oFSA) is a malignant, infiltrating, mesenchymal tumour affecting 16 
the oral cavity primarily of medium to large middle aged dogs. The diagnosis often is made late in 17 
the course of the disease, due to the frequent caudal location of the tumour, and histopathology is 18 
not always sufficient to discriminate undifferentiated oFSA from other poorly differentiated 19 
malignant mesenchymal tumours occurring at the same site, especially in small biopsy samples. The 20 
literature exclusively relating to oFSA is limited and outcome data following treatment are difficult 21 
to compare. The purpose of this article is to provide an overview of the literature spanning the last 22 
30 years, specifically with regard to different treatment modalities in their relation to prognosis of 23 
canine oFSA. 24 
 25 
Overall, the survival rate for dogs with oFSA has improved in recent years (overall survival 26 
247 to 743 days, as opposed to 30 - 540 days in papers published before 2000), probably due to 27 
better surgical planning. The major concern in clinical management of canine oFSA is the high 28 
local rate of recurrence (up to 57%), whereas metastasis occurs late in about 10-14% of affected 29 
dogs. Wide surgical excision is the mainstay of treatment. Initially, the tumour was considered to be 30 
radioresistant, but the combination of surgery and radiotherapy seems to be the most promising 31 
treatment modality at present. Despite a histopathological diagnosis of a low grade tumour, an 32 
aggressive treatment approach is always warranted to cure oFSA, but the ability to control local 33 
disease still represents the major challenge. 34 
 35 
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Introduction 37 
Oral tumours represent 6-7% of all canine malignancies and, among these, oral fibrosarcoma 38 
(oFSA) accounts for 8-25%, being the third most common malignant neoplasm of the oral cavity in 39 
dogs (Liptak and Withrow, 2013). The median age of dogs with oFSA at diagnosis is 8 years, which 40 
is slightly younger than dogs diagnosed with malignant melanoma and squamous cell carcinoma of 41 
the oral cavity (Liptak and Withrow, 2013). Dogs under 5 years of age at diagnosis are also reported 42 
(Todoroff and Brodey, 1979; Hoyt and Withrow, 1984). Medium to large breed dogs (> 20 kg) 43 
seem to be more commonly affected. There is no sex predilection, although male dogs are over-44 
represented in some studies (Todoroff and Brodey, 1979; Hoyt and Withrow, 1984). Golden 45 
retrievers are over-represented, especially in cases with a variant of the tumour characterised by an 46 
aggressive biological behaviour, known as ‘high-low’ oFSA, despite more benign histological 47 
features (Ciekot et al., 1994). 48 
 49 
Undifferentiated forms of oFSA may be difficult to distinguish histologically from other 50 
poorly differentiated malignant mesenchymal tumours affecting the oral cavity. In these cases, 51 
immunohistochemistry (IHC) may be needed to achieve the final diagnosis, even though few 52 
specific markers are available (Boy et al., 2005; Smedley et al., 2011; Munday et al., 2017; Ramos-53 
Vara and Borst, 2017). 54 
 55 
Most of the literature on oral tumours in dogs encompasses different histotypes and different 56 
treatment modalities; therefore, direct comparisons amongst papers are difficult to conduct. There 57 
are relatively few articles that focus exclusively on the treatment of canine oFSA and a more than 58 
10 year gap is evident between articles published in the 1990s and recent years (Thrall, 1981; 59 
Creasey and Thrall, 1982; Ciekot et al., 1994; Poirier et al., 2006; Frazier et al., 2012; Gardner et 60 
al., 2015; Milovancev et al., 2016). The aim of this paper is to review the literature relating to 61 
canine oFSA published within the past 30 years, focusing on the changes in treatment, prognosis 62 
and on the improvements made during this time span. Personal experience is also presented briefly 63 
(see Appendix: Supplementary Table 1). 64 
 65 
Clinical presentation of dogs with oral fibrosarcoma 66 
Oral FSAs in dogs usually appear as firm, pink to red, swellings or masses, frequently 67 
involving the gingiva of the maxilla, and the hard and soft palate; the underlying bone can be 68 
invaded in up to 72% of cases. As the tumour progresses, ulceration of the mass may occur, as well 69 
as facial deformity (Liptak and Withrow, 2013). Clinical signs may be minimal initially and owners 70 
may notice the problem only late in the course of the disease, especially for more caudally located 71 
tumours. In addition to facial swelling, other clinical signs may be drooling of blood-tinged saliva, 72 
when ulceration is present, and, less often, foul odour or difficulty in prehending food. 73 
 74 
‘High-low’ oral fibrosarcoma 75 
The growth rate of oFSA can be variable, depending on the histological grade. Ciekot et al. 76 
(1994) first described a unique subtype of FSA known as ‘histologically low grade, yet biologically 77 
high grade, fibrosarcoma’ (‘high-low’ FSA), which is characterised by a histologically low grade 78 
diagnosis despite a high grade clinical behaviour. Twenty-five dogs with ‘high-low’ oFSA were 79 
included in that study, with a range of 3 to 13 years of age (median 8 years). There was an almost 80 
even distribution among sexes, but a higher frequency (52%) in Golden retrievers. Sixteen tumours 81 
occurred in the maxilla. On histological examination, all specimens were characterised by 82 
‘haphazard proliferation of fibrous connective tissue with moderately low to low cellularity, 83 
abundant collagenous stroma, minimal nuclear pleomorphism, low mitotic rate, and poor 84 
demarcation from surrounding tissue. Invasion of the fibrous tissue into surrounding muscle and 85 
bone’ was sometimes evident. Some of the cases had been diagnosed previously as nodular fasciitis. 86 
The treatment of these dogs included variable combinations of radical surgery, radiation, 87 
chemotherapy and hyperthermia. The initial staging was negative for lung or lymph node 88 
metastasis, except for one dog that already had lymph node involvement; metastases to lung or 89 
lymph node subsequently developed in 12-20% of cases, respectively. Since then, this tumour entity 90 
has been widely recognised and it is now understood that the treatment should not differ from the 91 
standard for dogs with higher grade oFSAs. 92 
 93 
Establishing a diagnosis 94 
Clinical staging 95 
As for any malignant tumour, the first step is to establish a clear diagnosis, to evaluate the 96 
extent of local tumour infiltration and to screen for local and distant metastases (clinical staging). 97 
Staging includes thorough physical examination of the oral cavity and regional lymph nodes, three-98 
view thoracic radiographs, and complete pre-anaesthetic blood and heart evaluation. Since 99 
computed tomography (CT) is now widely available, it is usually preferred over radiography to 100 
evaluate the extent of infiltration of the primary tumour in the skull; CT also allows evaluation of 101 
adjacent bone invasion (Fig. 1 a, b), assists in surgical planning, and thoracic CT is more sensitive 102 
than radiographs in detecting lung metastasis (Ghirelli et al., 2013). Moreover, CT allows 103 
evaluation of local non-palpable lymph nodes, such as the medial retropharyngeal and parotid 104 
lymph nodes. However, a recent study contradicts this statement, showing that this diagnostic tool 105 
demonstrates poor sensitivity in the detection of lymph node metastasis from tumours of canine 106 
head, particularly for micrometastasis (Skinner et al., 2018). Magnetic resonance imaging (MRI) 107 
may also be used for staging purposes, as it is superior in evaluation of soft tissue involvement 108 
compared to CT (Vestraete, 2005; Johnson et al., 2016). 109 
 110 
Fine needle aspiration of any enlarged lymph node should be performed for clinical staging. 111 
However, lymphadenectomy and histology should be considered to reliably determine lymph node 112 
status. Fine needle aspiration of the primary mass is often unrewarding, because of the difficulty in 113 
collecting a sufficient number of cells for interpretive analysis by cytology, due to the intrinsic 114 
characteristics of mesenchymal tumours, and because of concurrent local inflammation and 115 
necrosis. An incisional biopsy of the primary mass is mandatory to achieve diagnosis (Harvey, 116 
1980; Richardson et al., 1983; Hoyt and Withrow, 1984; Vestraete, 2005). However, some authors 117 
argue that, since malignant histological type strongly influences survival, but has a minimal impact 118 
on the surgical plan, it may be left up to the clinician to propose whether or not to perform an 119 
incisional biopsy. This choice is based on the owner’s decision whether or not to treat depending on 120 
the prognosis, or on cases where there is doubt regarding the malignancy of the lesion or when 121 
treatment modalities other than surgery are preferred (Birchard and Carothers, 1990; Berg, 1998; 122 
Liptak and Lascelles, 2012). 123 
 124 
When performing an incisional biopsy of the primary mass, care should be taken to gain 125 
access to the lesion from the oral cavity instead through the skin, to avoid dissemination of the 126 
tumour. Accurate site and size of biopsy are also important, since necrosis and inflammation, which 127 
usually accompany tumour growth, could lead to false negative results. In some cases, multiple 128 
biopsies may be needed, since the diagnosis of oral fibrosarcoma is not always easy to reach and 129 
histopathology may not be sufficient. Incisional biopsies should not adversely affect the definitive 130 
surgical procedure; therefore, central sampling should be preferred over sampling the periphery of 131 
the tumour. 132 
 133 
Histopathology 134 
Many articles on histological classification of canine cutaneous and subcutaneous soft tissue 135 
sarcomas have been published (Avallone et al., 2007; McSporran 2009; Tamburini et al., 2010; 136 
Dennis et al., 2011; Zornhagen et al., 2014; Milovancev et al., 2015). However, few studies have 137 
focussed specifically on sarcomas located in the oral cavity, since these are traditionally considered 138 
to be a separate entity, characterised by a more local malignant biological behaviour compared to 139 
soft tissue sarcomas at other sites (Kuntz et al., 1997; Dennis et al., 2011; Bray, 2016). 140 
 141 
Histologically, oFSAs are composed of ‘moderately to poorly differentiated large spindle-142 
shaped cells that are arranged in interlacing bundles separated by small amounts of collagenous 143 
matrix’ (Munday et al., 2017). Less cellular differentiation and the presence of more frequent 144 
mitotic figures and necrosis, together with an infiltrative growth pattern, allow differentiation from 145 
fibroma. The distinction from odontogenic tumours is usually straightforward, unless odontogenic 146 
epithelium is not present; in this case, the location of the mass away from the dental arcade may 147 
help in the diagnosis. Oral osteosarcoma can be diagnosed when osteoid deposition, recognised as 148 
homogeneous eosinophilic extracellular material within the neoplasm, is evident (Munday et al., 149 
2017). 150 
 151 
Biopsy samples from oFSAs containing overlying and adjacent epithelium may increase the 152 
ability to differentiating this entity from oral spindleoid amelanotic melanocytic tumours, since the 153 
sensitivity of the specific melanocytic markers used by IHC may be low if intraepithelial nests of 154 
neoplastic cells (one of the criteria commonly used to identify melanocytic tumours) cannot be 155 
detected. This variant of oral melanoma may be difficult to differentiate from other spindle cell 156 
tumours of the oral cavity on the basis of histopathology alone. IHC with a panel of specific anti-157 
melanocytic antibodies, including anti-melanoma antibody (PNL2), melan-A, tyrosinase-related 158 
protein (TRP)-1 and TRP-2, was considered of aid in establishing a diagnosis (Smedley et al., 2011; 159 
Munday et al., 2017); other monoclonal antibodies such as anti-melanoma gp100 (S-100) and the 160 
Human Melanoma Black 45 (HMB45) may complete the panel for melanocytic tumours detection 161 
in dogs. IHC should be performed in cases in which histopathology alone is inconclusive, such as in 162 
poorly differentiated tumours; for example, positive immunostaining for myocyte markers, such as 163 
anti-actin and anti-desmin, may help in differentiating poorly differentiated oFSA from tumours of 164 
muscle origin, such as leiomyosarcoma (Boy et al., 2005), rhabdomyosarcoma and myoepithelial or 165 
myofibroblastic tumours. Fibrosarcomas usually also exhibit negative immunostaining for cluster of 166 
differentiation (CD) 31, anti-von Willebrand’s factor antibody (factor VIII-associated antigen) and 167 
CD34, as opposed to tumours of endothelial origin (haemangiosarcomas, lymphangiosarcomas) 168 
(Ramos-Vara and Borst, 2017).  169 
 170 
Treatment 171 
Since 1980, amongst articles on canine malignant oral tumours, only very few focus on oFSA 172 
exclusively or include a high number of cases, except for some in which the number of dogs with 173 
oFSA exceeds 20 (Todoroff and Brodey, 1979; Ciekot et al., 1994; Théon et al., 1997; Poirier et al., 174 
2006; Frazier et al., 2012; Gardner et al., 2015; Sarowitz et al., 2017). Moreover, most of these 175 
articles include dogs that have received a variety of different treatment modalities, and the 176 
diagnostic approach was not uniform, thus making comparisons difficult. 177 
 178 
Oral FSA in dogs is characterised by a high rate of recurrence, which can occur in up to 57% 179 
of cases (Todoroff and Brodey, 1979; Salisbury et al., 1986; Kosovsky et al., 1991; Schwarz et al., 180 
1991 a, b; Wallace et al., 1992; Lascelles et al., 2003; Frazier et al., 2012; Sarowitz et al., 2017). In 181 
contrast, distant metastases are less common, being detected in 0-35% of cases (Todoroff and 182 
Brodey, 1979; Salisbury and Lantz, 1988; Wallace et al., 1992; Ciekot et al., 1994; Poirier et al., 183 
2006; Frazier et al., 2012; Sarowitz et al., 2017). Therefore, the major challenge in treatment is 184 
achieving local control. En bloc excision plays an important role in accomplishing this goal, but 185 
multimodality treatment, primarily combining surgery and radiation therapy, is the mainstay of 186 
treatment (Hoyt and Withrow, 1984; Emms, 1987; Kosovsky et al., 1991; White, 1991; Wallace et 187 
al., 1992; Ciekot et al., 1994; Burk, 1996; Berg, 1998; Gardner et al., 2015; Sarowitz et al., 2017). 188 
 189 
Surgery 190 
Mandibulectomy and maxillectomy have become the routine methods for treating canine oral 191 
malignancies, with good clinical and functional outcome (Withrow and Holmberg, 1983; Bradley et 192 
al., 1984; White et al., 1985; Emms and Harvey, 1986; Salisbury et al., 1986; Salisbury and Lantz, 193 
1988; Birchard and Carothers, 1990; Kosovsky et al., 1991; Schwarz et al., 1991 a, b; White, 1991; 194 
Wallace et al., 1992; Fox et al., 1997; Lascelles et al., 2003, 2004; Vestraete, 2005; Sarowitz et al., 195 
2017). However, for oral malignancies, including oFSA, there is still debate about how to determine 196 
the safest surgical margins to limit local recurrence. CT or MRI evaluation of the primary lesion is 197 
helpful in determining such margins, mainly for caudally located tumours. Most authors report that 198 
at least 1 cm of macroscopically normal soft tissue or bone surrounding the tumour should be 199 
removed (Bradley et al., 1984; Hoyt and Withrow, 1984; Emms and Harvey, 1986; Kosovski et al., 200 
1991; Wallace et al., 1993; Berg, 1998; Frazier et al., 2012); whenever possible, a margin of 2-3 cm 201 
is preferable, but this may not be always possible to achieve (Liptak and Lascelles, 2012; Sarowitz 202 
et al., 2017). 203 
 204 
Information about the completeness of surgical excision is reported in some publications 205 
(Schwarz et al., 1991a, b; Ciekot et al., 1994; Forrest et al., 2000; Lascelles et al., 2003, 2004; 206 
Frazier et al., 2012; Gardner et al., 2015; Sarowitz et al., 2017). In larger studies, the proportion of 207 
dogs in which tumours could be removed with clean margins was never higher than 71% (Schwarz 208 
et al., 1991a). Technical limitations in margin evaluation still remain a challenge, despite 209 
improvements made in this field over the past few years and the growing awareness of surgeons to 210 
correctly prepare the tissue sample for the pathologist (Milovancev et al., 2017). The role of the 211 
tumour microenvironment in promoting tumour invasion and metastasis, as well as the concept of 212 
tumour heterogeneity, may help to explain the recurrence of ‘completely excised’ neoplasms 213 
(Milovancev and Russell, 2017). 214 
 215 
Radiotherapy 216 
In earlier studies, oFSA was considered a radioresistant tumour (Todoroff and Brodey, 1979; 217 
Harvey, 1980; Thrall, 1981; Richardson et al., 1983; Harvey, 1985; Emms, 1987; Vestraete, 2005). 218 
This was probably due to the limitations that came with orthovoltage radiation machines (Todoroff 219 
and Brodey, 1979; Thrall, 1981; Brewer and Turrel, 1982; Creasey and Thrall, 1982). The 220 
combination of orthovoltage radiation with the radiosensitiser misonidazole did not seem to 221 
improve the outcome and was associated with side effects (Creasey and Thrall, 1982). 222 
Hyperthermia has also been used together with orthovoltage radiotherapy (Brewer and Turrel, 1982; 223 
Schwarz et al., 1991a, b), but this combination is now rarely used, due to the difficulty in 224 
administering heating and the availability of more advanced radiotherapy machines. 225 
 226 
With the advent of megavoltage equipment, in fact, both the incidence and severity of side 227 
effects, and the overall results of treatment have improved considerably (Hoyt and Withrow, 1984; 228 
Burk, 1996; Théon et al., 1997; Berg, 1998; Dhaliwal et al., 1998; Forrest, 2000; Lascelles et al., 229 
2004; Poirier et al., 2006; Frazier et al., 2012; Gardner et al., 2015). Costs remain the major issue of 230 
this treatment modality, especially in some European countries. A high dose of radiation, > 50 Gy, 231 
is considered necessary to overcome radioresistance (Poirier et al., 2006). 232 
 233 
Radiotherapy alone, with a curative or palliative intent, may be useful for the treatment of 234 
canine oFSA, producing similar results to those of surgery alone. In a study conducted by Poirier et 235 
al. (2006) on macroscopic oral lesions, the overall times to progression and overall survival were 236 
205 and 310 days, respectively; this is not substantially different from what has been achieved 237 
through surgery alone (Lascelles et al., 2004; Sarowitz et al., 2017). Similar results were reported 238 
by Gardner et al. (2015) in a smaller group of dogs. 239 
 240 
In general, when a curative intent radiation protocol is attempted, a total dose of 40-60 Gy is 241 
administered in daily fractions of 3-4.2 Gy, on a Monday through Friday schedule, both in a 242 
macroscopic (Poirier et al., 2006) or adjuvant setting (Forrest et al., 2000; Gardner et al., 2015). For 243 
palliative purposes, coarsely fractionated protocols, consisting of the administration of a total dose 244 
of 24-30 Gy, delivered in three fractions of 8 Gy each or five fractions of 6 Gy each, have been 245 
proposed (Poirier et al., 2006). Nonetheless, oral FSA seems to be less sensitive to radiation when 246 
compared to the same histotype growing at other sites (Forrest et al., 2000). 247 
 248 
Within the past 15 years, the use of CT scanning for both the early detection of lung 249 
metastasis and for surgical planning has almost completely replaced the need for radiographs. 250 
Despite this, the recurrence rate still is as high as 54% (Sarowitz et al., 2017) to 57% (Lascelles et 251 
al., 2003) when surgery is the sole treatment modality. In the authors’ experience of a small case 252 
series of 13 oFSAs treated by surgery alone, the recurrence rate was 30.7%, and clean surgical 253 
margins could be obtained in 10/13 (76.9%) cases, most of which had CT performed as part of the 254 
surgical planning. The median disease-free interval was 317 days and median overall survival was 255 
not reached (see Appendix: Supplementary Table 1). A recently published article using the same 256 
treatment modality in eight dogs reported a median survival of 249 days and a median progression-257 
free survival of 138 days (Gardner et al. 2015). The combination of surgery and adjuvant 258 
megavoltage radiotherapy leads to an improvement of tumour control (recurrence rate 24.1%) and 259 
median overall survival (743 days), as reported by Frazier et al. (2012). 260 
 261 
Chemotherapy and targeted therapy 262 
Although chemotherapy has been used as adjuvant treatment for oFSA (Emms et al., 1986; 263 
Schwarz et al., 1991 a, b; Ciekot et al., 1994; Gardner et al., 2015), its role is still unclear and has 264 
not been investigated in detail. As for most sarcomas, oFSA is considered to be chemoresistant 265 
(Harvey, 1985). However, the most commonly administered drug in association with surgery and/or 266 
radiation is doxorubicin. Recently, the effect of two tyrosine kinase inhibitors (TKI), imatinib and 267 
masitinib, on canine oFSA cells and tissue samples was investigated, based on the premise that 268 
some canine oFSA samples and two canine oFSA cell lines expressed platelet-derived growth factor 269 
receptors (PDGFRs)-α and β (Milovancev et al., 2016). A mild inhibitory effect of both TKIs was 270 
observed in vitro, but at a concentration too high to be used in a clinical setting. The addition of 271 
doxorubicin in the cell culture slightly potentiated the action of the TKIs. This finding is worth 272 
further investigation in order to use these drugs as adjuvant cytotoxic drugs. A recent publication on 273 
dogs affected by malignant tumours showed that the combination of doxorubicin (at a slightly 274 
reduced dose) and toceranib appears to be safe (Pellin et al., 2017). Oral FSAs were not included in 275 
the study, but it might be worth investigating such a combination in this type of tumour. 276 
 277 
In two studies, vascular endothelial growth factor (VEGF) plasma concentrations were 278 
measured in dogs with various malignant and benign tumours, including oFSA (Wergin and Kaser-279 
Hotz, 2004; Sobczynska-Rak et al., 2014). In both studies, VEGF concentrations were lower in FSA 280 
compared to other malignant tumours, such as oral melanoma and squamous cell carcinoma; 281 
however, in the study of Wergin and Kaser-Hotz (2004) the location of the fibrosarcoma was not 282 
stated and it is not clear whether oFSA was included. 283 
 284 
There are no published data on the use of metronomic chemotherapy for palliative treatment 285 
of canine oFSA. This approach is based on the ‘oral administration of chemotherapy at relatively 286 
low, minimally toxic doses, on a frequent or continuous schedule of treatment, with no extended 287 
drug-free breaks’ (Gaspar et al., 2018). The more commonly used drugs are different combinations 288 
of cyclophosphamide, chlorambucil and lomustine, together with thalidomide, metformin, 289 
piroxicam or other anti-cyclooxygenases (COX) agents, in order to stimulate the host immune 290 
system, modify tumour microenvironment and act against tumour neoangiogenesis.  291 
The promising results obtained in dogs affected by soft tissue sarcomas at sites other than the 292 
oral cavity may encourage the use of metronomic chemotherapy for oFSA (Emslie et al., 2008; 293 
Burton et al., 2011). In particular, the disease-free interval of dogs with incompletely resected soft 294 
tissue sarcomas of the trunk and extremities was significantly longer when metronomic 295 
chemotherapy was administered (Emslie et al., 2008). 296 
 297 
The effects of electrochemogene therapy with a combination of bleomycin and interleukin 298 
(IL)-12 on different histotypes of spontaneous canine tumours were reported by Reed et al. (2010). 299 
This technique is based on the ability to increase cell permeability and allow movement of 300 
molecules into cells by the application of a series of square-wave electrical pulses (electroporation) 301 
to the tumour mass. This may be applied to both gene and drug therapy. In the study conducted by 302 
Reed et al. (2010) one inoperable oFSA was included, and an initial partial response was seen 303 
before progressive disease developed. The authors concluded that this tumour type might be 304 
partially responsive to this treatment, with mild side effects; therefore, this technique may be 305 
worthy of further investigation, mainly for non-resectable cases. 306 
 307 
Prognosis 308 
Local tumour control still represents the main challenge in canine oFSA. Literature beyond 309 
the year 2000 was chosen for evaluating prognosis of oFSA. Most of the articles published after that 310 
time included CT scanning as part of clinical staging, compared to previous reports where thoracic 311 
and skull radiographs were performed most frequently for clinical staging purposes. Including more 312 
advanced imaging modalities should have improved the ability to better plan the surgical excision. 313 
Nonetheless, the incidence of local recurrence has not improved as much as expected. 314 
 315 
One year survival 316 
 The one year survival, regardless of the type of treatment, is reported as 7-76% in studies 317 
published before 2000 (Todoroff and Brodey, 1979; Harvey, 1980; Thrall, 1981; Brewer and Turrel, 318 
1982; White, 1985; Emms and Harvey, 1986; Kosovsky et al., 1991; White, 1991; Wallace et al., 319 
1992; Théon et al., 1997) compared to 29.4-87.7% for studies published from 2000 to 2017 (Poirier 320 
et al., 2006; Frazier et al., 2012; Sarowitz et al., 2017; personal data, see Appendix: Supplementary 321 
Table 1). However, when analysing the data by Mann-Whitney U test (Prism v5.0, GraphPad 322 
Software), a statistically significant difference was not evident between these two periods (P = 0.23; 323 
Fig. 2). 324 
 325 
Overall survival time 326 
In contrast, when comparing overall survival time, a statistically significant improvement (P = 327 
0.035) was found among groups. The overall survival reported before the 2000 was 30-540 days 328 
(Todoroff and Brodey, 1979; Harvey, 1980; Thrall, 1981; Brewer and Turrel, 1982; Bradley et al., 329 
1984; Emms et al., 1986; Salisbury et al., 1986; Salisbury and Lantz, 1988; Kosovsky et al., 1991; 330 
Schwarz et al.,1991 a, b; Wallace et al., 1992; Fox et al., 1997) compared to 247-743 days reported 331 
in later studies (Forrest et al., 2000; Poirier et al., 2006; Ohlerth et al., 2010; Frazier et al., 2012; 332 
Gardner et al., 2015; Sarowitz et al., 2017) (Fig. 3). The difference between the one-year and 333 
overall survival could be explained in part by the low number of cases in many of the papers 334 
considered, that may have influenced this result. The biology of the tumour, that can be sometimes 335 
slow-growing, could also influence the time to progression (both in terms of time to recurrence or 336 
metastasis), since it may be longer than one year, thus resulting in a statistically different survival 337 
only on the long run. A prospective study enrolling an adequate number of cases followed for at 338 
least 2 years would be warranted to clarify this issue. 339 
 340 
Metastasis    341 
The metastatic rate has not changed substantially throughout the years (P = 0.40); a range of 342 
0-38.4% is reported in earlier publications (Todoroff and Brodey, 1979; Bradley et al., 1984; White 343 
et al., 1985; Emms and Harvey, 1986; Salisbury et al., 1986; Salisbury and Lantz, 1988; Kosovsky 344 
et al., 1991; Schwarz et al.,1991 a, b; White, 1991; Wallace et al., 1992; Ciekot et al., 1994; Théon 345 
et al., 1997), compared to 0-23% more recently (Lascelles et al., 2003, 2004; Poirier et al., 2006; 346 
Frazier et al., 2012; Sarowitz et al., 2017; personal data, see Appendix: Supplementary Table 1) 347 
(Fig. 4). 348 
 349 
Recurrence 350 
 The recurrence rate was 5-87.5% in earlier publications (Todoroff and Brodey, 1979; 351 
Harvey et al., 1980; Thrall, 1981; Brewer and Turrel, 1982; Creasey and Thrall, 1982; Withrow and 352 
Holmberg, 1983; Bradley et al., 1984; White et al., 1985; Emms and Harvey, 1986; Salisbury et al., 353 
1986; Salisbury and Lantz, 1988; Kosovsky et al., 1991; Schwarz et al.,1991a, b; White, 1991; 354 
Wallace et al., 1992; Ciekot et al., 1994; Théon et al., 1997), compared to 24.1-57.1% in more 355 
recent reports (Lascelles et al., 2003, 2004; Frazier et al., 2012; Sarowitz et al., 2017; personal data 356 
in Supplementary files); these ranges are not significantly different (P = 0.68; Fig. 5). 357 
 358 
Time to recurrence 359 
Similarly, the time to recurrence has not changed significantly between the two evaluated 360 
time periods (P = 0.26); before 2000, tumours recurred after 75-1260 days (Todoroff and Brodey, 361 
1979; Harvey, 1980; Thrall, 1981; Brewer and Turrel, 1982; White, 1985; Emms and Harvey, 1986; 362 
Kosovsky et al., 1991; White, 1991; Wallace et al., 1992; Théon et al., 1997), whereas the time to 363 
recurrence was 145-1368 days in the more recent literature (Forrest et al., 2000; Lascelles et al., 364 
2004; Poirier et al., 2006; Frazier et al., 2012; Gardner et al., 2015; Sarowitz et al., 2017; personal 365 
data, see Appendix: Supplementary Table 1). 366 
 367 
Prognostic factors 368 
A few authors have evaluated prognostic factors for long-term survival and disease-free 369 
interval. Tumour stage, tumour site (more caudally located masses have a worse prognosis), and 370 
completeness of surgical excision were reported most frequently (Salisbury and Lantz, 1988; 371 
Schwarz et al., 1991 a, b; Wallace et al., 1992; Théon et al., 1997; Gardner et al., 2015; Sarowitz et 372 
al., 2017). 373 
 374 
Conclusions 375 
Oral FSA is a malignant, infiltrating mesenchymal tumour affecting the oral cavity of middle-376 
aged dogs. The diagnosis is often made late in the course of the disease because of the frequent 377 
caudal location of the tumour. Distant metastases are rarely evident at presentation. Although 378 
histopathology may be compatible with a low-grade tumour, an aggressive approach is always 379 
warranted to obtain local control of this invasive tumour. Within the last 30 years, some 380 
improvements have been made in equipment for radiotherapy and in the surgical procedures 381 
available, but the prognosis for this tumour is still guarded. Treatment failure is often due to local 382 
tumour recurrence that can still occur in up to 54% of cases. A thorough staging based on CT 383 
examination and wide/radical surgical excision is fundamental to eradicate the tumour. Adjuvant 384 
treatments, such as radiation therapy, are recommended in order to prolong both the disease-free 385 
interval and survival time. A rigorous analysis of the published literature is challenging due to small 386 
case series and the many different treatment modalities that were included even in the same study; 387 
therefore, the data presented here should be considered cautiously. Nevertheless, an improvement in 388 
survival has occurred in recent years, and an optimistic view on the possibility to cure this tumour is 389 
justified. Prospective studies focusing on oral FSA and investigating the roles of cytotoxic and 390 
targeted chemotherapy, as well as radiotherapy, would be needed to clearly address the best 391 
treatment options for this tumour in dogs. 392 
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Figure legends 633 
 634 
Fig. 1. Computed tomography (CT) images of an oral mass diagnosed as fibrosarcoma. (a) Post 635 
contrast scan showing bone involvement of the maxilla and invasion into the nasal cavity. (b) Soft 636 
tissue involvement in the same dog. In this case, surgery was not performed since the owners 637 
refused neoadjuvant radiation following surgical debulking. 638 
 639 
Fig. 2. One year survival rate reported by different authors before (7-76%) and after (29.4 - 87.7%) 640 
the year 2000. Various combinations of surgery, radiotherapy, hyperthermia, chemotherapy were 641 
used in different studies. The difference between the two groups is not statistically different (P = 642 
0.23). 643 
 644 
Fig. 3. Overall survival reported by different authors before (30-6204 days) and after (247-743 645 
days) the year 2000. Different combinations of treatment were used. A significant improvement in 646 
survival in recent years was evident (P = 0.035). 647 
 648 
Fig. 4. Metastatic rate reported by different authors before (0-38%) and after (0-23%) the year 2000. 649 
There was no significant difference between time periods (P = 0.40). 650 
 651 
Fig. 5. Median recurrence rate reported before (5-87.5%) and after (24.1-57.1%) the year 2000. A 652 
significant improvement in tumour control has not been achieved (P = 0.68). 653 
 654 
Fig. 6. Median time to recurrence before (75-1260 days) and after (145- 1368 days) the year 2000. 655 
There was no significant difference between time periods (P = 0.26). 656 
